-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EMB-07 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EMB-07 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EMB-07 in Metastatic Pancreatic Cancer Drug Details: EMB-07 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JNJ-8543 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JNJ-8543 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JNJ-8543 in Diffuse Large B-Cell Lymphoma Drug Details: JNJ-80948543...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-303 in Diabetic Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-303 in Diabetic Nephropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-303 in Diabetic Nephropathy Drug Details: AP-303 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-301 in Hyperphosphatemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-301 in Hyperphosphatemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-301 in Hyperphosphatemia Drug Details: VS-505 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AP-306 in Hyperphosphatemia In Chronic Kidney Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AP-306 in Hyperphosphatemia In Chronic Kidney Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AP-306 in Hyperphosphatemia In Chronic Kidney Disease Drug Details:...
-
Product Insights
NewGlomerulonephritis – Drugs In Development, 2024
Empower your strategies with our Glomerulonephritis – Drugs In Development, 2024 report and make more profitable business decisions. Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family...
-
Product Insights
NewIgA Nephropathy (Berger’s Disease) – Drugs In Development, 2024
Empower your strategies with our IgA Nephropathy (Berger's Disease) – Drugs In Development, 2024 report and make more profitable business decisions. IgA nephropathy, also known as Berger's disease, is a kidney disorder characterized by the buildup of the antibody immunoglobulin A (IgA) in the small blood vessels (glomeruli) within the kidneys. This condition can lead to inflammation, damage, and scarring of the kidneys, affecting their ability to filter waste and excess fluids from the blood. The exact cause of IgA nephropathy...
-
Product Insights
NewPolycystic Kidney Disease – Drugs In Development, 2024
Empower your strategies with our Polycystic Kidney Disease – Drugs In Development, 2024 report and make more profitable business decisions. Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. PKD symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination, and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. The Polycystic Kidney Disease drugs in development market research report provide...
-
Product Insights
NewHyperphosphatemia – Drugs In Development, 2024
Empower your strategies with our Hyperphosphatemia – Drugs In Development, 2024 report and make more profitable business decisions. Hyperphosphatemia is an electrolyte disorder in which there is an elevated level of phosphate in the blood. Causes include kidney failure, pseudohypoparathyroidism, hypoparathyroidism, diabetic ketoacidosis, tumor lysis syndrome, and rhabdomyolysis.[1] Diagnosis is generally based on a blood phosphate levels of greater than 1.46 mmol/L (4.5 mg/dL). Signs and symptoms include ectopic calcification, secondary hyperparathyroidism, and renal osteodystrophy. Abnormalities in phosphate metabolism such as...